Full text is available at the source.
Abstract
mRNA vaccines may offer significant advantages in oncology, including rapid development and safety.
- Clinical translation of mRNA vaccines faces challenges like instability and inefficient delivery.
- Advancements in molecular design include both non-replicating and self-amplifying RNAs.
- Lipid nanoparticles (LNPs) have been identified as effective delivery strategies to enhance stability and immune response.
- Different administration routes may influence the strength of antitumor immunity.
- The review categorizes antigens as viral, tumor-associated, and neoantigens, highlighting their roles in vaccine effectiveness.
- Innovative uses of mRNA to encode immunomodulators may help reprogram the immunosuppressive tumor microenvironment.
Simplified